An Open-Label, Single-Center, 2-Part, Parallel Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of [14C]E7386 in Healthy Male Subjects
Latest Information Update: 25 Sep 2023
At a glance
- Drugs Eribulin (Primary) ; Eribulin (Primary)
- Indications Breast cancer; Colorectal cancer; Ewing's sarcoma; Glioblastoma; Haemangioendothelioma; Haemangiosarcoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eisai Co Ltd
- 19 Sep 2023 Status changed from recruiting to completed.
- 30 Aug 2023 Planned End Date changed from 31 Aug 2023 to 29 Sep 2023.
- 30 Aug 2023 Planned primary completion date changed from 31 Aug 2023 to 29 Sep 2023.